[go: up one dir, main page]

AR125390A1 - Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona - Google Patents

Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona

Info

Publication number
AR125390A1
AR125390A1 ARP220101017A ARP220101017A AR125390A1 AR 125390 A1 AR125390 A1 AR 125390A1 AR P220101017 A ARP220101017 A AR P220101017A AR P220101017 A ARP220101017 A AR P220101017A AR 125390 A1 AR125390 A1 AR 125390A1
Authority
AR
Argentina
Prior art keywords
dioxopiperidin
isoindoline
dione
benzyl
amino
Prior art date
Application number
ARP220101017A
Other languages
English (en)
Inventor
Tonia J Buchholz
Michael Pourdehnad
Poliana Alves Patah
Fan Wu
Original Assignee
Celgene Corp
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Bristol Myers Squibb Co filed Critical Celgene Corp
Publication of AR125390A1 publication Critical patent/AR125390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se proporcionan métodos para usar (S)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino) isoindolina-1,3-diona, o un enantiómero, una mezcla de enantiómeros, un tautómero, un isotopólogo o una de sus sales farmacéuticamente aceptables, en combinación con tafasitamab, obinutuzumab o tazemetostat, para tratar, prevenir o controlar el linfoma no Hodgkin.
ARP220101017A 2021-04-21 2022-04-20 Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona AR125390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163177616P 2021-04-21 2021-04-21

Publications (1)

Publication Number Publication Date
AR125390A1 true AR125390A1 (es) 2023-07-12

Family

ID=81648544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101017A AR125390A1 (es) 2021-04-21 2022-04-20 Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona

Country Status (13)

Country Link
US (2) US20220362255A1 (es)
EP (1) EP4326275A1 (es)
JP (1) JP2024515108A (es)
KR (1) KR20230172491A (es)
CN (1) CN117241802A (es)
AR (1) AR125390A1 (es)
AU (1) AU2022263424A1 (es)
BR (1) BR112023021015A2 (es)
CA (1) CA3211950A1 (es)
IL (1) IL305624A (es)
MX (1) MX2023012294A (es)
TW (1) TW202308644A (es)
WO (1) WO2022226011A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2019050924A1 (en) * 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
MX2020011183A (es) * 2018-04-23 2020-11-12 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
WO2020072445A1 (en) * 2018-10-01 2020-04-09 Verastem, Inc. Combination therapies
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Also Published As

Publication number Publication date
EP4326275A1 (en) 2024-02-28
US20220362255A1 (en) 2022-11-17
MX2023012294A (es) 2023-10-26
US20250017941A1 (en) 2025-01-16
JP2024515108A (ja) 2024-04-04
TW202308644A (zh) 2023-03-01
WO2022226011A1 (en) 2022-10-27
CA3211950A1 (en) 2022-10-27
KR20230172491A (ko) 2023-12-22
IL305624A (en) 2023-11-01
AU2022263424A1 (en) 2023-09-28
BR112023021015A2 (pt) 2023-12-19
CN117241802A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
CL2021002651A1 (es) Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona
CL2022000991A1 (es) Métodos de tratamiento de la leucemia linfocítica crónica con 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
PE20081894A1 (es) Derivados de isoindolina 4'-o-sustituidos y composiciones que los comprenden y metodos para usarlos
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
PE20160529A1 (es) Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas
PH12020552088A1 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
PH12020500211A1 (en) Methods of treating behavior alterations
MX380531B (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CL2024003328A1 (es) Métodos para el tratamiento de linfoma.
LT4048278T (lt) Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną
AR125390A1 (es) Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona
PE20160898A1 (es) (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
AR102562A1 (es) Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina
BR112022007150A2 (pt) Métodos de tratamento de leucemia linfocítica crônica usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
BR112023019943A2 (pt) Métodos de tratamento de linfoma de células b usando terapia combinada
MX2023012911A (es) Metodos de tratamiento del mieloma multiple usando terapia combinada.
NI201000185A (es) Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer.
DK1631291T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes
BR112022002802A2 (pt) Administração intratecal de levetiracetam